Lysine-Dendrimer, a New Non-Aggressive Solution to Rebalance the Microbiota of Acne-Prone Skin

Acne is a chronic inflammatory skin disease that affects the quality of life of patients. Several treatments exist for acne, but their effectiveness tends to decrease over time due to increasing resistance to treatment and associated side effects. To circumvent these issues, a new approach has emerg...

Full description

Saved in:
Bibliographic Details
Main Authors: Julie Leignadier (Author), Marie Drago (Author), Olivier Lesouhaitier (Author), Magalie Barreau (Author), Albert Dashi (Author), Oliver Worsley (Author), Joan Attia-Vigneau (Author)
Format: Book
Published: MDPI AG, 2023-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_34817523271a428c8da51ae7fb744ee1
042 |a dc 
100 1 0 |a Julie Leignadier  |e author 
700 1 0 |a Marie Drago  |e author 
700 1 0 |a Olivier Lesouhaitier  |e author 
700 1 0 |a Magalie Barreau  |e author 
700 1 0 |a Albert Dashi  |e author 
700 1 0 |a Oliver Worsley  |e author 
700 1 0 |a Joan Attia-Vigneau  |e author 
245 0 0 |a Lysine-Dendrimer, a New Non-Aggressive Solution to Rebalance the Microbiota of Acne-Prone Skin 
260 |b MDPI AG,   |c 2023-08-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15082083 
500 |a 1999-4923 
520 |a Acne is a chronic inflammatory skin disease that affects the quality of life of patients. Several treatments exist for acne, but their effectiveness tends to decrease over time due to increasing resistance to treatment and associated side effects. To circumvent these issues, a new approach has emerged that involves combating the pathogen <i>Cutibacterium acnes</i> while maintaining the homeostasis of the skin microbiome. Recently, it was shown that the use of a G2 lysine dendrigraft (G2 dendrimer) could specifically decrease the <i>C. acnes</i> phylotype (IAI) involved in acne, compared to non-acne-causing <i>C. acnes</i> (phylotype II) bacteria. In the present study, we demonstrate that the efficacy of this technology is related to its 3D structure, which, in contrast to the linear form, significantly decreases the inflammation factor (IL-8) linked to acne. In addition, our in-vitro data confirm the specific activity of the G2 dendrimer: after treatment of bacterial cultures and biofilms, the G2 dendrimer affected neither non-acneic <i>C. acnes</i> nor commensal bacteria of the skin (<i>Staphylococcus epidermidis</i>, <i>S. hominis,</i> and <i>Corynebacterium minutissimum</i>). In parallel, comparative in-vitro and in-vivo studies with traditional over-the-counter molecules showed G2's effects on the survival of commensal bacteria and the reduction of acne outbreaks. Finally, metagenomic analysis of the cutaneous microbiota of volunteers who applied a finished cosmetic product containing the G2 dendrimer confirmed the ability of G2 to rebalance cutaneous acne microbiota dysbiosis while maintaining commensal bacteria. These results confirm the value of using this G2 dendrimer to gently prevent the appearance of acne vulgaris while respecting the cutaneous microbiota. 
546 |a EN 
690 |a acne 
690 |a dendrimer 
690 |a lysine 
690 |a microbial diversity 
690 |a clinical studies 
690 |a biofilm 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 8, p 2083 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/8/2083 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/34817523271a428c8da51ae7fb744ee1  |z Connect to this object online.